Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
出版年份 2022 全文链接
标题
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
作者
关键词
-
出版物
JOURNAL OF HEPATOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-11-10
DOI
10.1016/j.jhep.2022.10.023
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Breakthroughs in therapies for NASH and remaining challenges
- (2022) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease
- (2022) Daniel Q. Huang et al. Clinical Gastroenterology and Hepatology
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Mechanisms and disease consequences of nonalcoholic fatty liver disease
- (2021) Rohit Loomba et al. CELL
- Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study
- (2021) Masatoshi Hara et al. Clinical and Experimental Nephrology
- Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
- (2021) Nobuharu Tamaki et al. GUT
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
- (2021) Cynthia Delgado et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
- (2021) Bethan L. Clifford et al. Cell Metabolism
- Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
- (2021) Lesley A. Inker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
- (2021) Anneli Andersson et al. Clinical Gastroenterology and Hepatology
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- NAFLD as a driver of chronic kidney disease
- (2020) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Tu1665 OBETICHOLIC ACID IMPROVES HEPATIC FIBROINFLAMMATION AS ASSESSED BY MULTIPARAMETRIC MRI: INTERIM RESULTS OF THE REGENERATE TRIAL
- (2020) Rohit Loomba et al. GASTROENTEROLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Simultaneous Glomerular Filtration Rate Determination Using Inulin, Iohexol and 99mTc-DTPA Demonstrates the Need for Customized Measurement Protocols
- (2020) Christine A. White et al. KIDNEY INTERNATIONAL
- Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease
- (2020) Arjun N.A. Jayaswal et al. LIVER INTERNATIONAL
- Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
- (2020) Jonathan G. Stine et al. Clinical Gastroenterology and Hepatology
- Dysregulated lipid metabolism links NAFLD to cardiovascular disease
- (2020) Audrey Deprince et al. Molecular Metabolism
- Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
- (2020) Alessandro Mantovani et al. GUT
- The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction
- (2019) Shen Li et al. FASEB JOURNAL
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Predicting NASH response with liver fat: Are we back to square one?
- (2019) Vincent Wai-Sun Wong JOURNAL OF HEPATOLOGY
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
- (2018) Mazen Noureddin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
- (2018) Romeo Papazyan et al. JOURNAL OF LIPID RESEARCH
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
- (2017) Oscar Chávez-Talavera et al. GASTROENTEROLOGY
- Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study
- (2017) Dong Hyun Sinn et al. JOURNAL OF HEPATOLOGY
- Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity
- (2017) Michael Pavlides et al. LIVER INTERNATIONAL
- Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation
- (2017) Yimeng Zhang et al. TOXICOLOGY
- Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
- (2017) Zhibo Gai et al. Scientific Reports
- Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease
- (2016) Michael Pavlides et al. JOURNAL OF HEPATOLOGY
- Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study
- (2016) Shozab S. Ali et al. Nutrition & Metabolism
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
- (2014) Eun Hui Bae et al. PLoS One
- Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus
- (2013) A Reich et al. ACTA DERMATO-VENEREOLOGICA
- Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
- (2013) Rajarshi Banerjee et al. JOURNAL OF HEPATOLOGY
- Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of γ-glutamyltransferase expression
- (2011) Chandra Ravuri et al. FREE RADICAL RESEARCH
- A Role of the Bile Salt Receptor FXR in Atherosclerosis
- (2010) Jurre Hageman et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The 5-D itch scale: a new measure of pruritus
- (2009) S. Elman et al. BRITISH JOURNAL OF DERMATOLOGY
- Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice
- (2009) Helen B. Hartman et al. JOURNAL OF LIPID RESEARCH
- Antiatherosclerotic effect of farnesoid X receptor
- (2008) Andrea Mencarelli et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More